Spinocerebellar Ataxia Type 27B: Disability Progression and 4-Aminopyridine Response

Overview

Spinocerebellar ataxia type 27B (SCA27B) is a rare neurogenetic condition that mainly affects balance. The condition was only discovered in 2023, but is already proving to be a common cause of late-onset balance issues. I combined and analyzed data from all existing studies to assess how disability progresses over time and to review early evidence on a medication called 4-aminopyridine, which was originally developed for another condition but might be effective at treating SCA27B. Overall, disability progression was slow–more than 60% of patients could still walk unaided by age 70. Furthermore, over 90% of patients across studies reported a meaningful positive response to 4-aminopyridine, though the trial designs had important limitations. In all, my work helps SCA27B patients better understand their prognosis and highlights the need for larger studies to confirm the effectiveness of 4-AP and ultimately improve access to the medication.

Awards (2)

• Bronze Medal
• Selected for CWSF 2026

Competition history

• CWSF 2026 Disease & Illness

Related projects

Closest projects by meaning, across every fair and year in the corpus.